Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -170.94% is 43% below its 2-year average of -119.16%, near the low end of its 2-year range (-187.33%–-10.31%).
As of the fiscal period ended Tuesday, June 30, 2026. 98.33% below its 12-month average of -86.19%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-06-30): -170.94%.
RETURN ON EQUITY (ROE)
-170.94%
RETURN ON EQUITY (ROE) AVG TTM
-86.19%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-98.33%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-306.90%
vs the sector median at left
Lite Strategy, Inc.
Market Cap
$48.15M
Return on Equity (ROE)
-170.94%
TTM Avg
-86.19%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$49.47M
Return on Equity (ROE)
-17.84%
TTM Avg
-32.49%
3Y Avg
-23.88%
5Y Avg
-18.14%
Market Cap
$48.92M
Return on Equity (ROE)
N/A
TTM Avg
-206.96%
3Y Avg
-221.50%
5Y Avg
-349.91%
Market Cap
$49.21M
Return on Equity (ROE)
N/A
TTM Avg
-374.04%
3Y Avg
-326.22%
5Y Avg
-254.86%
Market Cap
$49.90M
Return on Equity (ROE)
-23.70%
TTM Avg
-170.56%
3Y Avg
-190.10%
5Y Avg
-146.13%
Market Cap
$49.52M
Return on Equity (ROE)
N/A
TTM Avg
-382.07%
3Y Avg
-282.25%
5Y Avg
-171.00%
Market Cap
$47.41M
Return on Equity (ROE)
-28.20%
TTM Avg
-53.22%
3Y Avg
-59.23%
5Y Avg
-46.35%
Market Cap
$49.55M
Return on Equity (ROE)
-42.01%
TTM Avg
-2.07%
3Y Avg
11.82%
5Y Avg
5.22%
Market Cap
$49.58M
Return on Equity (ROE)
-90.44%
TTM Avg
-163.19%
3Y Avg
-112.62%
5Y Avg
-86.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lite Strategy, Inc. (LITS) | $48.15M | -170.94% | -86.19% | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | -17.84% | -32.49% | -23.88% | -18.14% |
| Celularity Inc. (CELU)vs › | $48.92M | N/A | -206.96% | -221.50% | -349.91% |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | -374.04% | -326.22% | -254.86% |
| Microbot Medical Inc. (MBOT)vs › | $49.90M | -23.70% | -170.56% | -190.10% | -146.13% |
| Apollomics, Inc. (APLM)vs › | $49.52M | N/A | -382.07% | -282.25% | -171.00% |
| Instil Bio, Inc. (TIL)vs › | $47.41M | -28.20% | -53.22% | -59.23% | -46.35% |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.55M | -42.01% | -2.07% | 11.82% | 5.22% |
| INmune Bio, Inc. (INMB)vs › | $49.58M | -90.44% | -163.19% | -112.62% | -86.58% |
| Envoy Medical, Inc. (COCH)vs › | $50.56M | -708.48% | 156.13% | 510.26% | 342.91% |
ROE
-170.9%
ROA
-166.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -170.94% |
| 2026-03-31 | -107.01% |
| 2025-12-31 | -48.50% |
| 2025-09-30 | -10.31% |
| 2025-06-30 | -94.18% |
| 2025-03-31 | -162.03% |
| 2024-12-31 | -172.94% |
| 2024-09-30 | -187.33% |
